| |
HIV & HCV Highlights from Recent Conferences: ASM/ICAAC - Pharmacology Workshop - DDW
New HIV & HCV Drugs / Inflammation-Heart Disease-Statin, TDF PrEP new studies / Cabotegravir Update: Long-Acting Treatment & Prevention / CMV-Aging
|
| |
| |
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
June 8-10, 2016, Washington DC
DDW - Digestive Disease Week 2016
San Diego, CA May 16-19, 2016
The International Liver Congress™
EASL - European Association for the Study of the Liver
Barcelona, Spain 13-17 April 2016
Dolutegravir Regimens for Highly Treatment Experienced
Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects - (06/24/16)
Switch to Dolutegravir plus Rilpivirine dual therapy in cART-Experienced Subjects: an Italian cohort - (06/24/16)
New HIV Drug PRO-140
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients - (06/22/16)
New Long-Acting HIV Nucleoside
Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - (06/14/15)
New HCV Regimen FDA Approval June 28
Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates in Patients With Negative Predictors of Response to Treatment: an Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (06/06/16)
The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis - (06/08/16)
New HCV Regimen Completing Phase 3 Now
HIGH SVR RATES WITH THE COMBINATION OF ABT-493 + ABT-530 FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 OR 2 INFECTION - (05/26/16)
SURVEYOR-I: 100% SVR12 AND FAVORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED FOR 12 WEEKS IN NON-CIRRHOTIC PATIENTS WITH GENOTYPES 4, 5, OR 6 INFECTION - (05/26/16)
Pitavaststin Reduces Arterial Inflammation / Immune Activation / LDL Better than Pravastatin
ASM: Effects of Pitavastatin on Markers of Arterial Inflammation and Immune Activation in HIV Patients - (06/24/16) .....lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific marker of vascular inflammation associated with atherosclerosis.3 Following production by inflammatory cells, this enzyme cleaves oxidized phospholipids, generating pro-inflammatory molecules and oxidized fatty acids.
Inflammation plays a central role in the development of atherosclerosis and the Lp-PLA2 enzyme is hypothesized to play a causal role in its pathogenesis.......In this article, we will review the evidence to support the notion that Lp-PLA2 is causally implicated in the pathobiology of atherogenesis and discuss the potential utility of inhibiting this enzyme as a therapeutic target......http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107429/
TAF - Bones /Renal 96 Weeks - in Patients at High-Risk for renal disease / Diabetics with Renal Disease / Women with Renal Disease
ASM/ICAAC: Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate Regimen to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment - (06/23/16)
ASM/ICAAC: Switch From TDF Regimens to E/C/F/TAF Is Associated With Improved Bone Mineral Density, Decreased Serum PTH, and Decreased Bone Turnover Biomarkers - (06/23/16)
ASM/ICAAC: Switching from TDF to TAF in Patients with High Risk for CKD - (06/21/16)
ASM/ICAAC: Tenofovir Alafenamide in Participants with Diabetes and Renal Impairment: Renal Safety Through 96 Weeks - (06/21/16)
Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Women With Renal Impairment: 96-Week Results - (06/21/16)
New Integrase Inhibitor GS-9883
Discovery of Bictegravir (GS-9883), a Novel, Unboosted, Once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Improved Pharmacokinetics and In Vitro Resistance Profile - (06/20/16)
Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1-Infected Patients - (06/20/16)
Antiviral Activity of Bictegravir (GS-9883), a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor - (06/20/16)
Bictegravir (GS-9883), a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile - (06/20/16)
Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV - (06/20/16)
TAF PK -
ASM/ICAAC: Tenofovir Alafenamide Has Wide Efficacious Range for Treatment of HIV-1 Infection: Pharmacokinetic-Pharmacodynamic Relationship From a Phase 3 Study - (06/24/16)
ASM/ICAAC: Enhanced Exposure of Tenofovir-Diphosphate in Peripheral Blood Mononuclear Cells by Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (06/24/16)
ASM/ICAAC: Pharmacokinetics-Pharmacodynamics of Emtricitabine/Tenofovir Alafenamide Demonstrated Wide Exposure Range Associated With Clinical Safety - (06/24/16)
Pharm: Pharmacokinetic Interaction Between Emtricitabine/ Tenofovir Alafenamide and Boosted Atazanavir - (06/14/15)
Tenofovir PrEP 2 new studies: “500% increase in PrEP.....49,158 have started FTC/TDF for PrEP from 2012-2015....low among African-Americans, women, Hispanics <25 years old"
ASM/ICAAC: Racial Characteristics of FTC/TDF for Pre-exposure Prophylaxis (PrEP) Users in the US - (06/22/16)
ASM: HIV-1 Seroconversion Across 17 International Demonstration Projects Using Pre-exposure Prophylaxis (PrEP) With Oral Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) - (06/22/16)
Pharm: In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies - (06/22/15)
Cabotegravir Update – Long-Acting HIV Treatment & Prevention, Phase 3 Trials
Pharm: Cabotegravir Long-Acting (LA) Injectable Nanosuspension - (06/16/15)
CMV & Aging
The immunological footprint of CMV in HIV-1 patients stable on long-term ART..... CMV / "accelerated ageing" in HIV+ - (06/15/16)
CROI: Effect of CMV and HIV replication on T cell exhaustion and senescence during ART - (06/13/16)
CROI: Persistent elevation of inflammation markers in HIV+ persons with Cytomegalovirus disease - (06/13/16)
|
|
| |
| |
|
|
|
